Navigation Links
Auxogyn Licenses Non-invasive Embryo Assessment Technology From Stanford University
Date:10/4/2010

MENLO PARK, Calif., Oct. 4 /PRNewswire/ -- Auxogyn, Inc., a privately held medical technology company focused on women's reproductive health, today announced that it acquired an exclusive license from Stanford University to develop a set of products that may allow medical practitioners in the field of assisted reproduction to significantly improve the effectiveness of in vitro fertilization (IVF) procedures.

The technology licensed from Stanford is described in a publication titled 'Non-invasive imaging of human embryos before embryonic genome activation predicts development to the blastocyst stage,' now appearing in the online edition of Nature Biotechnology. This landmark study demonstrated, for the first time, that human embryo fate is already determined at the four-cell stage of development. The article is authored by Professor Renee Reijo Pera, Dr. Connie Wong, Dr. Kevin Loewke, Dr. Nancy Bossert, Dr. Barry Behr, Dr. Christopher De Jonge and Dr. Thomas Baer and showed that measuring a unique set of non-invasive imaging parameters by day 2 may allow an embryologist to predict the embryos that will reach the blastocyst (day 5) stage of development with a very high degree of accuracy.

"Blastocyst formation is a critical time point in human embryo development and provides more objective criteria for selecting which embryo(s) to transfer," said Lissa Goldenstein, president and chief executive officer of Auxogyn, Inc.  "For years, researchers have searched for ways to predict the embryos most likely to reach the blastocyst stage in order to enable earlier transfer and ultimately improve live-birth rates for in vitro fertilization procedures."

"Building on the technology licensed from Stanford, we are developing a product that assesses early embryo viability at the 4-cell stage. We believe that generating key clinical data assessments may enable embryologists to improve the effectiveness of in vitro fertilization (IVF) procedures while providing women experiencing infertility the highest quality of patient care," continued Ms. Goldenstein.

About Auxogyn

Auxogyn is a privately held medical technology company focused on advancing women's reproductive health by applying its novel scientific and clinical knowledge of early human developmental biology to the field of assisted reproduction and in vitro fertilization (IVF) procedures. Auxogyn's first product in development combines a proprietary computational algorithm with developmental biology imaging capabilities to assess early embryo viability at the four-cell stage of development by identifying embryos that have the possibility of developing into a blastocyst.  Auxogyn is funded by the leading life science venture firms Kleiner Perkins Caufield & Byers, TPG Biotechnology and Merck Serono Ventures. For more information regarding Auxogyn please visit www.auxogyn.com.


'/>"/>
SOURCE Auxogyn, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
2. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
3. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
4. Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
5. Stem Cell Sciences Licenses Stem Cell Technology to Leading Provider of Genetically Modified Models for Pharmaceutical Research
6. Arizona Heart Innovative Technologies Licenses New Endovascular Device
7. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
8. Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University
9. Implicit Licenses Clinical Stage Antibody Program From Lilly
10. Global Med Technologies(R) Licenses 90th Site in the Southeastern U.S.
11. Nanosys Licenses Nanowire Technology to QuantuMDx Group for Next Generation Diagnostic and Sequencing Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
(Date:10/10/2017)... ... October 10, 2017 , ... For ... has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled ... Volunteer Experience from US2020. , US2020’s mission is to change the trajectory of ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:5/23/2017)... 23, 2017  Hunova, the first robotic gym for the rehabilitation and ... launched in Genoa, Italy . The first 30 robots ... the USA . The technology was developed and patented ... the IIT spin-off Movendo Technology thanks to a 10 million euro investment ... please click: ...
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
Breaking Biology News(10 mins):